INOVIO to Participate in Upcoming Investor Conferences in May


PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May:

(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)

The Citizens JMP Life Sciences Conference
Date: Tuesday, May 14, 2024
Time: 11:30 AM ET
Presenter: Dr. Jacqueline Shea, President & CEO
Format: Fireside Chat

RBC Capital Markets 2024 Global Healthcare Conference
Date: Wednesday, May 15, 2024
Time: 10:00 AM ET
Presenter: Dr. Jacqueline Shea, President & CEO
Format: Fireside Chat

H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Date: Monday, May 20, 2024
Time: 12:30 PM ET
Presenter: Dr. Jacqueline Shea, President & CEO
Format: Fireside Chat

During the conferences, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

Webcasts of the fireside chats will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. Replays of the webcasts will be available for 90 days after the date of the presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-investor-conferences-in-may-302129665.html

SOURCE INOVIO Pharmaceuticals, Inc.

Werbung

Inovio Pharmaceuticals Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Inovio Pharmaceuticals nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
15.02.18 Inovio Pharmaceuticals Buy Maxim Group
18.10.17 Inovio Pharmaceuticals Outperform RBC Capital Markets
24.05.17 Inovio Pharmaceuticals Buy Maxim Group
16.03.17 Inovio Pharmaceuticals Buy Maxim Group
07.11.16 Inovio Pharmaceuticals Buy Aegis Capital

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.